Literature DB >> 8912458

Production and characterization of a reconstituted high density lipoprotein for therapeutic applications.

P G Lerch1, V Förtsch, G Hodler, R Bolli.   

Abstract

A method is described for the large scale preparation of reconstituted high density lipoproteins (rHDL) suitable for therapeutic use. Apolipoprotein A-I (apoA-I was isolated from precipitates obtained by cold ethanol fractionation of human plasma. This process includes several steps for virus removal and virus inactivation, among them pasteurization. Reconstitution of lipoprotein particles was performed by cholate dialysis using soybean phosphatidylcholine as the lipid source. An apoA-I:lipid ratio of 1:150 (mol:mol) was obtained. Redissolved rHDLs were disc-shaped particles resembling nascent HDL, as assessed by electron microscopy. The method was optimized for low content of free apoA-I protein as well as the low concentration of free lipid. The product was stabilized by lyophilization in the presence of sucrose. In vitro studies show potential effects it the prevention of gram-negative septic shock and in the inhibition of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912458     DOI: 10.1046/j.1423-0410.1996.7130155.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  38 in total

Review 1.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

2.  Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins.

Authors:  Philippe Marmillot; Sanket Patel; M Raj Lakshman
Journal:  Metabolism       Date:  2007-02       Impact factor: 8.694

3.  Host cell P-glycoprotein is essential for cholesterol uptake and replication of Toxoplasma gondii.

Authors:  Iveta Bottova; Adrian B Hehl; Sasa Stefanić; Gemma Fabriàs; Josefina Casas; Elisabeth Schraner; Jean Pieters; Sabrina Sonda
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

Review 4.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 5.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

6.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia.

Authors:  D Pajkrt; J E Doran; F Koster; P G Lerch; B Arnet; T van der Poll; J W ten Cate; S J van Deventer
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

Review 7.  Learning from biology: synthetic lipoproteins for drug delivery.

Authors:  Huang Huang; William Cruz; Juan Chen; Gang Zheng
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-10-24

8.  High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.

Authors:  Seth G Thacker; Abdalrahman Zarzour; Ye Chen; Mustafa S Alcicek; Lita A Freeman; Dennis O Sviridov; Stephen J Demosky; Alan T Remaley
Journal:  Immunology       Date:  2016-08-28       Impact factor: 7.397

Review 9.  Lipoproteins and lipoprotein mimetics for imaging and drug delivery.

Authors:  C Shad Thaxton; Jonathan S Rink; Pratap C Naha; David P Cormode
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

10.  Suppression of nuclear factor-kappaB activity in macrophages by chylomicron remnants: modulation by the fatty acid composition of the particles.

Authors:  Clara De Pascale; Valerie Graham; Robert C Fowkes; Caroline P D Wheeler-Jones; Kathleen M Botham
Journal:  FEBS J       Date:  2009-09-02       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.